When restricting our analyses to participants with initially mild or moderate COVID-19, no difference in IL10 levels between participants with and without PASC remained at 21–24 weeks; however, the higher levels of IL1β and sCD14 observed among participants with PASC compared to those without PASC remained (S3 Fig in S1 File). The gene discussed is IL10; the disease is COVID-19.